Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.31 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14186549 | 0.86 | — | — | |
| SCHEMBL8247109 | 0.84 | — | — | |
| SCHEMBL22958273 | 0.84 | — | — | |
| SCHEMBL12494581 | 0.84 | — | — | |
| SCHEMBL23839182 | 0.84 | — | — | |
| SCHEMBL24521730 | 0.84 | — | — | |
| SCHEMBL31887 | 0.84 | — | — | |
| SCHEMBL20860322 | 0.84 | — | — | |
| SCHEMBL20860351 | 0.84 | — | — | |
| SCHEMBL15181015 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | MEN1 1878/4885NPC1 4482/4885RAB9A 2954/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | MEN1 1601/4885NPC1 4675/4885RAB9A 3432/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | MEN1 1878/4885NPC1 4482/4885RAB9A 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.